Levetiracetam monotherapy for primary generalised epilepsy

Seizure

Volumn 12, Issue 3, 2003, Pages 150-153

  Cohen, Jeffrey ^a  

^a Beth Israel Singer Division   (United States)

Author keywords

Generalised epilepsy; Levetiracetum; Myoclonus

Indexed keywords

ANTACID AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; HISTAMINE H2 RECEPTOR ANTAGONIST; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; SERTRALINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID;

ABDOMINAL PAIN; ABSENCE; ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT DISORDER; CASE REPORT; COGNITIVE DEFECT; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; FATIGUE; GENERALIZED EPILEPSY; HUMAN; MALE; MONOTHERAPY; MUSCLE WEAKNESS; MYOCLONUS EPILEPSY; NEPHROLITHIASIS; PRIORITY JOURNAL; RASH; SPEECH DISORDER; SPIKE WAVE; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0037387616     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1059-1311(02)00273-X     Document Type: Article

References (14)

1. Shorvon, S. Handbook of Epilepsy Treatment. London, Blackwell Science, 2000.
2. Perucca, E. The management of refractory idiopathic epilepsies. Epilepsia 2001; 42 (Suppl. 3): 31-35.
3. Cereghino, J. J., Biton, V., Abou-Khalil, B. et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-242.
4. Shorvon, S. D., Lowenthal, A., Janz, D. et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179-1186.
5. Ben-Menachem, E. and Falter, U. Efficacy and tolerability of levetiracetam 3000 mg in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41: 1276-1283.
6. Privitera, M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia 2001; 42 (Suppl. 4): 31-35.
7. Harden, C. Safety profile of levetiracetam. Epilepsia 2001; 42 (Suppl. 4): 36-39.
8. Data on File. Smyrna, GA, UCB Pharma, Inc., 2001.
9. Faught, E. Pharmacokinetic considerations in prescribing antiepileptic drugs. Epilepsia 2001; 42 (Suppl. 4): 19-23.
10. Leppik, I. E. Issues in the treatment of epilepsy. Epilepsia 2001; 42 (Suppl. 4): 1-6.
11. I b i d.
12. Topiramate product information. In: Physicians Desk Reference, 54th edn. Montvale, NJ, Medical Economics Co., Inc., 2000: pp. 2209-2216.
13. Betts, T., Waegemans, T. and Crawford, P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80-87.
14. Loscher, W. and Honack, D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. European Journal of Pharmacology 1993; 232: 147-158.